The estimated Net Worth of Michael J. Garrison is at least $155 ezer dollars as of 13 July 2015. Michael Garrison owns over 7,343 units of Bio-Path Inc stock worth over $155,200 and over the last 12 years Michael sold BPTH stock worth over $0.
Michael has made over 5 trades of the Bio-Path Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Michael bought 7,343 units of BPTH stock worth $8,958 on 13 July 2015.
The largest trade Michael's ever made was buying 340,000 units of Bio-Path Inc stock on 12 June 2013 worth over $102,000. On average, Michael trades about 34,005 units every 54 days since 2012. As of 13 July 2015 Michael still owns at least 160,000 units of Bio-Path Inc stock.
You can see the complete history of Michael Garrison stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is 8900 E Pinnacle Peak Rd e200, Scottsdale, AZ 85255, USA.
Over the last 16 years, insiders at Bio-Path Inc have traded over $171,456 worth of Bio-Path Inc stock and bought 1,226,067 units worth $451,466 . The most active insiders traders include Capital, Llc Armistice Capi..., Thomas E Garrison és Michael J. Garrison. On average, Bio-Path Inc executives and independent directors trade stock every 423 days with the average trade being worth of $156,477. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 18 January 2019, trading 64,457 units of BPTH stock currently worth $171,456.
bio-path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary dnabilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. the company’s initial focus is in oncology. bio-path’s lead product candidate, prexigebersen, (bp1001), is in phase ii clinical trials for aml in combination with ldac in elderly de novo patients. the safety segment of the phase ii trial for prexigebersen + dasatinib in blast-phase and accelerated phase cml patients is expected to begin in 2017. bio-path’s second drug candidate, bp1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. the technology behind prexigebersen is called dnabilize™ technology. dnabilize is a liposomal antisense dna platform with two critical improvements in oligonucleotide therapeutics. the main benefits to the patient are, 1: we have never had a single patient experience thrombocytopen
Bio-Path Inc executives and other stock owners filed with the SEC include: